Form 4: Carl L. Gordon Acquires 40,000 Stock Options in Compass Therapeutics

Director and 10% owner Carl L. Gordon acquired 40,000 stock options in Compass Therapeutics on February 11, 2025, according to a recent SEC Form 4 filing.

Summary

• Carl L. Gordon, a director and 10% owner of Compass Therapeutics, Inc. (CMPX), acquired 40,000 stock options on February 11, 2025.
• The options have an exercise price of $3.65.
• The options vest over 48 months starting March 11, 2025.
• The options expire on February 11, 2035.
• Gordon is a member of OrbiMed Advisors LLC and is obligated to transfer any securities or economic benefits from these options to OrbiMed Advisors and OrbiMed Capital GP V LLC, which will then provide them to OrbiMed Private Investments V-KA, LP.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing related to stock option grants. It doesn't contain any particularly positive or negative information, hence a neutral sentiment score.

Industry Context

This filing reflects standard executive compensation practices within the biotechnology industry, where stock options are frequently used to incentivize and retain key personnel. The vesting schedule and transfer obligations to OrbiMed are typical arrangements for individuals affiliated with investment firms.

Comparison to Industry Standards

• Stock option grants are a common form of compensation in the biotech industry, often used to align the interests of management with those of shareholders.
• Vesting schedules of 48 months are standard practice to ensure long-term commitment.
• Similar arrangements can be seen at companies like Moderna (MRNA) and BioNTech (BNTX), where executives receive stock options that vest over several years.
• The transfer obligation to OrbiMed is similar to arrangements seen in other portfolio companies of venture capital firms, ensuring that the investment firm benefits from the executive's performance.

Related Party Transactions

• The Reporting Person is a member of OrbiMed Advisors LLC and is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and OrbiMed Capital GP V LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V-KA, LP.

Stakeholder Impact

• The granting of stock options can incentivize management to improve company performance, potentially benefiting shareholders.
• The arrangement with OrbiMed ensures that the investment firm's interests are aligned with the company's success.

Key Dates